E2F3 and neoplasm: In endometrial cancer, miR-152 inhibited tumor cell growth via targeting novel candidate targets E2F transcription factor 3 (E2F3), tyrosine kinase receptor (MET), and rapamycin-insensitive companion of mTOR (Rictor) [21].